Anastrozole

About

Therapy type: Hormone therapy

Therapy strategy: Aromatase inhibition

Mappings

NCI Thesaurus: Anastrozole (coding:ncit:C1607)

RxNorm: anastrozole (coding:rxcui:84857, coding:omop:1348265)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (2) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab